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Abstract
Acute postoperative infectious endophthalmitis remains one of the most 
dreaded complications of ophthalmic surgery. One of the keys to success in treating 
this complication is to make an early clinical diagnosis and, if possible, an etiologic 
diagnosis that can guide treatment with antibiotic therapy. Different antibiotic 
therapy modalities have emerged over the years that have made it possible to treat 
even resistant strains of various microorganisms that cause endophthalmitis. 
Another relevant advance made in the etiological diagnosis of endophthalmitis is 
the advent of molecular biology techniques, such as the real-time polymerase chain 
reaction, which can detect minimal amounts of the genetic material of the caus-
ative microorganism present in the vitreous in a short period of time, thus improv-
ing treatment outcomes with better-guided therapy with intravitreal antibiotics. 
Aside from advances in postoperative diagnosis methods, the surgical treatment 
of endophthalmitis has had significant improvements in vitrectomy techniques, 
and in many cases, it has been proposed as the first-line treatment concomitantly 
with intravitreal antibiotic therapy. Moreover, there is increasing evidence that 
prophylaxis with intracameral antibiotic therapy further decreases postoperative 
endophthalmitis incidence.
Keywords: Acute postoperative endophthalmitis, vitrectomy, intravitreal antibiotics, 
polymerase chain reaction
1. Introduction
Acute postoperative infectious endophthalmitis (APIE) is an uncommon 
complication of eye surgery. It generally causes severe inflammation, which could 
significantly damage the ocular tissues and often has a poor prognosis, especially if 
it is not diagnosed and treated promptly [1–4].
APIE etiology is varied, being bacterial, the most frequent cause [3, 4]. Different 
ways to corroborate the microbiological diagnosis, such as a Gram staining on a 
smear and culture, have been described [2, 4]. Nonetheless, the use of molecular 
biology methods like the polymerase chain reaction (PCR) and other novel diagnos-
tic tests has increased the speed and accuracy of etiologic diagnosis [2].
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For several decades, intravitreal antibiotics injection (IAI) has been one of 
APIE treatment’s mainstays [3, 4]. In recent years, the application of new antibiotic 
classes has been described, especially to treat APIE caused by resistant strains of the 
most prevalent causative pathogens [5]. Moreover, vitrectomy has become a crucial 
adjunctive therapeutic modality for infectious endophthalmitis [3–7]. Thanks to 
development in instrumentation and vitrectomy systems, visual results in APIE 
patients have consistently improved in recent years [6, 7].
2. Epidemiology
The incidence of APIE after cataract surgery has decreased considerably in the 
era of small incision surgery. In some reports, the incidence of APIE ranges from 
0.12% to 1–3% [6, 7]. In patients undergoing trabeculectomy, the risk of devel-
oping endophthalmitis at five years is 1.1%, and the cumulative risk at 20 years 
can be as high as 20% [2–6, 8, 9]. The rate of endophthalmitis after endothelial 
keratoplasty and penetrating keratoplasty has been reported in up to 0.2% and 
0.7%, respectively [10]. Regarding vitrectomy, the incidence of endophthalmitis 
tends to be relatively low. Some publications indicate an incidence of 0.05 to 0.06% 
[6]. Incidence of APIE following intravitreal injection of anti-VEGF agents is also 
infrequent. In one series of 10,164 injections only 3 cases of endophthalmitis were 
reported (0.030%) [1].
3. Risk factors
Multiple factors increase the likelihood of APIE in patients undergoing intra-
ocular surgery. Some intraoperative complications such as posterior capsular 
rupture with or without vitreous loss, hypotony with aqueous humor filtra-
tion, especially in cases of clear corneal wounds and increased manipulation of 
intraocular tissues, are some factors that may raise the possibility of developing 
infectious endophthalmitis [3, 4, 11, 12].
The presence of inflammatory-infectious processes on the ocular surface or 
adnexa, such as conjunctivitis, keratitis, blepharitis, and dacryocystitis also, 
increases the incidence of endophthalmitis [4]. Additional systemic factors include 
advanced age [12] and chronic systemic debilitating diseases, such as diabetes 
mellitus (DM), malignancies, congenital or acquired immunodeficiencies and 
immunosuppression [3, 4, 12]. Patients with DM represent significant changes in 
the conjunctival flora, representing an important subgroup of patients who might 
develop endophthalmitis [3, 4].
APIE risk factors after anti-VEGF intravitreal injections, include not wearing a 
face mask, not using povidone prior to the injection and speaking while performing 
the injection [12].
A systematic review and meta-analysis [11] of the risk factors for APIE follow-
ing cataract surgery, reported that there is a significant association between male 
gender and APIE. The overall OR for male gender was 1.43 (95% CI 1.29, 1.58). 
There was a significant association between extra- or intracapsular cataract extrac-
tion and APIE (OR 2.19, 95% CI 1.40, 3.42) compared with phacoemulsification. 
Furthermore, intracameral cefuroxime had a protective effect against APIE com-
pared with topical antibiotics alone (OR 5.48, 95% CI 3.79, 7.92).
Analysis of the included retrospective studies in the meta-analysis showed that 
posterior capsular rupture was also a significant risk factor of APIE (OR 6.33, 95% 
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CI 4.22, 9.49), and a significant increase in risk of APIE with other intraoperative 
complications (OR 4.95, 95% CI 2.31, 10.63) was observed, as well.
4. Etiology
Multiple microorganisms may cause APIE [3, 4]. Bacterial pathogens are the 
most common [4]. Gram-positive cocci are responsible for 65–80% of APIE cases, 
mainly Staphylococcus spp. [12, 13].
Staphylococci belong to the Micrococcaceae family and have a diameter of 
between 0.2 and 12 microns [3, 14, 15]. The most common staphylococci spe-
cies that cause endophthalmitis are coagulase-negative Staphylococci and 
Staphylococcus aureus.
Among all Staphylococci, Staphylococcus epidermidis, a coagulase-negative 
staphylococci, has emerged as the main cause of APIE [4, 13]. These bacteria have 
the property of producing an exopolysaccharide, which can be a factor that hampers 
phagocytosis and induces antibiotic resistance, including methicillin and beta-
lactam antibiotics. However, these microorganisms are almost always susceptible to 
vancomycin [3].
Staphylococcus aureus is a non-spore-forming facultative aerobic microorgan-
ism that colonizes human skin. It produces different enzymes such as catalase, 
coagulase, beta-lactamase, many of which, are related to its pathogenicity  
[14, 15]. Staphylococcus aureus is the second most common bacteria isolated in 
cases of APIE [3, 13].
Other causes of APIE include Streptococci, Gram-positive bacilli, Gram-
negative cocci, and Gram-negative bacilli [4].
Streptococci are facultative Gram-positive, aerobic microorganisms or obligate 
anaerobes and produce various toxins that increase their virulence. They are also 
sensitive to vancomycin [3].
Gram-positive bacilli causative agents of endophthalmitis include bacteria from 
the Bacillus genus. The most common intraocular Gram-positive bacilli pathogen is 
Bacillus cereus [3, 4]. Bacillus is a spore-forming rod that is Gram-positive or Gram-
variable. It produces extracellular products, including toxins that induce severe 
inflammation when injected into the eye. Bacillus infection risk factors include 
foreign bodies, immunosuppression from malignant tumors, corticosteroid use, 
penetrating and perforating trauma, as well as acquired immunodeficiency syn-
drome. The infection is quite virulent and may significantly damage the eye in less 
than 24 hours. Systemically, it may induce fever and leukocytosis [3]. Vancomycin is 
the first-line drug used against Bacillus spp.
The genus Pseudomonas are Gram-negative, strictly aerobic organisms found in 
soil and water. They are part of the normal human flora but are predominantly iso-
lated in cases of nosocomial infection [3]. Pseudomonas aeruginosa is the most com-
mon Gram-negative bacteria causing APIE, but other species have also been isolated 
[3, 16]. The pathogenesis of the infectious disease caused by Pseudomonas includes 
the production of extracellular enzymes and other toxic proteins and hemolysin, 
endotoxin, and exotoxin A, which explain the fulminant and severe nature of its 
clinical presentation [3]. Pseudomonas spp. are usually sensitive to aminoglycosides 
and ceftazidime [3].
Other bacteria members of the Enterobacteriaceae family may cause APIE. 
Enterobacteriaceae is a group of Gram-negative, facultative aerobes. They are 
distributed in the soil and plants, and colonize the human and animals’ gastrointes-
tinal tract [3].
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Fungal endophthalmitis is an infrequent cause of APIE; however, it should 
be considered as a possible pathogen [4]. Candida, Aspergillus spp, Histoplasma, 
and Blastomyces dermatitidis are some of the fungal microorganisms that may 
cause APIE.
Candida albicans is frequently found as part of the normal flora on the mucosal 
surfaces, and is the most common cause of fungal APIE, followed by Aspergillus 
spp. Patients that become immunocompromised by debilitating conditions such as 
AIDS, and other malignancies may also carry a higher risk for developing Candida 
APIE Table 1 [4]. Summarizes the most frequently isolated microorganisms in 
different types of eye surgery.
5. Diagnosis
5.1 Signs and symptoms
The diagnosis of APIE is eminently clinical at onset. Intraocular surgery, mainly 
cataract surgery, is usually a painless procedure in the vast majority of cases [4, 12]. 
The sudden appearance of red eye, pain, and blurred vision as symptoms in the 
early postoperative period of patients that have undergone any intraocular surgery 
should always alert the surgeon to the possibility of APIE, although it is considered 
a rare but feared and devastating postoperative complication [3].
Common signs that may occur at onset are palpebral erythema and edema, 
ciliary injection, and conjunctival chemosis, corneal edema, hypopyon, anterior 
chamber cells, and vitreous haze due to vitritis (Figures 1 and 2). It is essential 
to mention that most endophthalmitis cases present between the third and tenth 
postoperative day, and 88% of the cases occur within six weeks after surgery 
(Table 2) [3, 4].
Fundus evaluation should be performed to determine the vitreous clarity, and to 
establish the status of the retina and the optic nerve. If fundus visualization is not 
feasible, linear B-ultrasound examination is mandatory to evaluate the posterior 
segment and rule out vitreous hemorrhage, retained lens material, retinal detach-
ment, choroidal thickening, or the presence of membranes [4, 17].
5.2 Microbiology diagnosis
Samples obtained from anterior-chamber aspiration and vitreous needle 
biopsy or pars plana vitrectomy (PPV) should be process for smear and cultured 
Type of surgery Most frequently isolated microorganisms
Cataract Gram-positive bacteria (95% of culture-positive isolates). 70% of gram-
positive bacteria are coagulase-negative Staphylococci




Streptococcus species, Staphlycoccus and Haemophilus influenzae
Vitrectomy Gram-positive cocci account for more than 90% positive cultures
Penetrating keratoplasty Coagulase-negative Staphylococci and Methicillin-resistant Staphylococcus 
aureus
Table 1. 
Most frequently isolated microorganisms in different types of eye surgery [10, 12].
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separately. The sample obtained from the vitreous should be undiluted and 
taken directly from the vitrectomy line. This has the potential advantage of 
having an adequate amount of bacterial load to grow in the culture plates, thus 
increasing the sensitivity of the culture to identify the possible APIE causative 
microorganism.
Alternatively, cassette washings from PPV should be concentrated by a 
centrifuge before culture and staining [3, 4]. Samples are placed on glass slides 
and stained using Gram and Giemsa stains. Obtained samples are plated on blood, 
thioglycolate, chocolate, and Saboraud agars and cultured under both, anaerobic 
and aerobic conditions. Whenever possible, it is advisable to place the obtained 
samples directly on agar plates in the operating room for better yield. They 
should be at room temperature by the time they are used, avoiding using them 
at refrigeration temperature because microbial growth might be reduced. Care 
should be taken to avoid contamination while placing the samples on the plates or 
transport media.
Figure 1. 
Clinical image of a case of an acute postoperative infectious endophthalmitis caused by Pseudomonas 
aeruginosa, showing prominent ciliary injection and conjunctival chemosis, a 3 mm hypopyon, and marked 
anterior chamber inflammatory infiltrate that obstructs visualizing the anterior segment details.
Figure 2. 
Clinical image of a case of an infectious endophthalmitis 3 days after phacoemulsification surgery caused by 
Staphylococcus epidermidis. The presence of hypopyon, corneal folds and edema, ciliary injection and cloudy 
media are observed.
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The endophthalmitis vitrectomy study (EVS) study reported positive cultures 
from 69.3% of biopsied cases using traditional agar plates and broth culture  
methods [13].
These conventional microbiology methods are commonly used for labora-
tory identification and antibiotic sensitivity tests of pathogens in APIE cases. 
Disadvantages of culture, include a low sensitivity and specificity for bacterial 
detection in the aqueous and vitreous humor, and are time-consuming [3, 4]. 
Nonetheless, whenever a minimal suspicion of infectious endophthalmitis exists, 
smear and culture are mandatory. Vitreous sample for culture gets a better yield 
than aqueous humour.
Disadvantages of lack of a microbiological confirmation in cases of APIE include 
non-response to IAI, increased morbidity from prolonged infection, repeated 
biopsies and IAI, and the potential to require performing more surgeries [4].
6.  Polymerase chain reaction techniques and other novel methodologies 
for the diagnosis of acute postoperative endophthalmitis
Since the advent of PCR, molecular laboratory techniques have increased 
rapidly. Its use is part of many routine processing of clinical samples in microbiol-
ogy laboratories, establishing a new era for diagnosing infectious diseases [17]. The 
use of PCR for APIE diagnosis increases significantly bacterial detection sensitiv-
ity and speed for etiologic diagnosis in vitreous and aqueous humors. The bacteria 
detection rate in aqueous and vitreous samples increased from approximately 48% 
to up to 95% using PCR techniques [17–21].
PCR and nested PCR protocols followed by post-PCR techniques such as 
RFLP (restriction fragment length polymorphism), DNA sequencing, and DNA-
probe hybridization have all been utilized to improve the etiologic diagnosis of 
APIE [22, 23].
Reported sensitivities for bacterial identification in vitreous samples for 
several PCR techniques like nested PCR and real-time multiplex PCR are 84%, 
and 90–95%, respectively, although reported sensitivities vary among different 
publications [17].
Real-time PCR technology (RT-PCR) is a modification and enhancement of the 
PCR technique. It is a homogeneous technique in which DNA amplification and 
detection of the target sequence co-occur, decreasing PCR products’ handling and 








Loss of fundus visualization 79%
Corneal infiltrate 5%
Table 2. 
Percentage of presentation of common symptoms and signs in acute postoperative infectious 
endophthalmitis [4].
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risks of carryover contamination. Simultaneous DNA amplification and detection 
allow higher reliability as compared to other traditional multi-step techniques. One 
of the main advantages of real-time PCR technology is the rapid access to results, 
with microbial detection times of 30 to 50 minutes, compared to 1–14 days for 
previous PCR methods [18–21].
Green 16S rDNA–Based Universal PCR (SGRU-PCR) and a Multiplex Gram-
Specific TaqMan–Based PCR (MGST-PCR) are useful for microorganism detection 
in many culture-negative samples. In one study, 90% were PCR positive among 
ten microbiologically negative samples, and five gave interpretable sequence data 
[17]. The pathogens identified included one coagulase-negative Staphylococcus, 
one Moraxella spp., and two Streptococcus mitis group, all APIE causative bacteria. 
Sequencing of PCR-positive/culture-negative samples also included the identifica-
tion of a Proteus spp. causing APIE, which is a rare causative microorganism in 
postoperative endophthalmitis [17].
Albeit being useful in APIE diagnosis, molecular identification of pathogen 
microorganisms remains an expensive technique. It is not available in many small 
cities, underdeveloped countries, laboratory settings, and in many instances, it 
requires a high workload that makes it inadequate for routine use. Furthermore, 
clinical definitions of some species do not match those used for 16S rRNA identifi-
cation [17, 18].
Among another novel microbial detection methods that could eventually be 
used in the expedite diagnosis of APIE cases are Matrix-Assisted Laser Desorption 
Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS) [24, 25] and the 
utilization of magneto-DNA nanoparticle Dovepress system [26]. The latter method 
was reported to simultaneously identify up to thirteen species of bacteria in under 
two hours [26].
Bacterial recognition directly from samples and colonies using MALDI-TOF 
MS has been described as a revolutionary method that better adapts to the clini-
cal microbiology laboratory. MALDI-TOF MS is used to identify bacterial species 
and to detect microorganisms previously misidentified [24]. Moreover, detection 
of antimicrobial resistance using MALDI-TOF MS has been reported for many 
bacteria, including Escherichia coli and Staphylococcus aureus. Another advantage of 
MALDI-TOF MS is that the time required for pathogen identification declines by 
55-fold and 169-fold and the cost by 5-fold and 96-fold compared with culture and 
molecular gene sequencing, respectively [24, 25].
The Magneto-DNA nanoparticle Dovepress system is an assay that utilizes mag-
netic nanoparticles and oligonucleotide probes to detect target nucleic acids from 
the pathogen. Rather than sequencing the whole RNA strand, a series of primers and 
probes were established to amplify and detect specific regions of interest within com-
mon bacterial types. They used a miniaturized micro-nuclear magnetic resonance sys-
tem that requires only small volumes of sample for processing for signal readout [26].
It is hypothesized that ribosomal RNA sequence information from microorga-
nisms such as bacteria could be used in a robust magneto-DNA assay. Because this 
magnetic detection strategy allows near background-free sensing, the assay steps 
are greatly simplified, and detection is much faster [26].
7. Treatment of acute postoperative infectious endophthalmitis
7.1 Intravitreal antibiotics and other pharmacologic therapies
Initial and one of the mainstays of treatment for APIE include intravitreal anti-
biotic therapy [3–5, 12]. Treatment with IAI should be started empirically before 
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having any culture results. For many years, the EVS conclusions and recommended 
IAI had been a paradigm in APIE patients’ care [4, 12]. Nonetheless, it is currently 
critical in most cases that clinical judgment should be used to determine treatment 
on a case-by-case basis. Moreover, first-line IAI recommendations have changed 
after EVS was published and, some authors have proposed vitrectomy as a concomi-
tant treatment of IAI, for the treatment of APIE [27–29].
The EVS was a prospective, multicenter, randomized clinical trial evaluating 
the efficacy of immediate PPV and intravenous antibiotics to treat APIE. The EVS 
included endophthalmitis cases after cataract surgery. Patients were randomized 
to either vitrectomy or vitreous needle biopsy and intravenous antibiotics or no 
intravenous antibiotics [4, 13, 30]. The study endpoints were media clarity and 
best-corrected visual acuity. Patients received vancomycin and amikacin IAI. 
Furthermore, subconjunctival ceftazidime, vancomycin, dexamethasone, topical 
vancomycin, amikacin, cycloplegic, 1% topical prednisolone acetate and 30 mg bid 
of oral prednisone, for 5–10 days were prescribed as well [13, 30].
The EVS conclusions included no difference in final vision or media clarity 
whether or not intravenous antibiotics were used. In addition, patients with light 
perception visual acuity who received PPV had a three-fold increment in the prob-
ability of achieving 20/40, and a 50% reduction in the probability of severe visual 
loss than patients receiving only vitreous needle biopsy [13].
Patients with hand-motions or better vision showed no significant difference in 
final best-corrected visual acuity or media clarity whether or not an early vitrec-
tomy was performed.
IAI recommendations have changed over the years. Initial treatment includes 
mainly intravitreal, as well as oral and topical antibiotics. Currently, two antibiotics 
are recommended by most retina specialists as first-line IAI treatment for APIE:
• Vancomycin (1 mg in 0.1 ml), and
• Ceftazidime (2.5 mg in 0.1 ml) [4, 11].
Vancomycin and/or amikacin are considered as intravitreal antibiotics alterna-
tives in cases of cephalosporin allergy and/or the presence of ceftazidime resistant 
Gram-negative strains. Vancomycin has an excellent Gram-positive coverage despite 
isolated reports of resistance (Table 3) [4].
For fungal APE cases, voriconazole, 50–100 μg/0.1 ml, and amphotericine B, 
5–10 μg/0.1 ml are described as first-line treatments.
Ceftazidime has emerged as first-line treatment for Gram-negative organisms 
due to its safer profile than amikacin. Another advantage of ceftazidime is that it 
may show synergy with vancomycin against gram-positive organisms [4, 12]. Oral, 
subconjunctival, and systemic antibiotics are used as adjuvant therapy in some 
hospital settings, although there is little or no evidence of their clinical effectiveness 
[3, 12]. Among all systemic antibiotics, ciprofloxacin is a first-generation fluoroqui-
nolone that has been routinely used in APIE due to adequate ocular penetration and 
low side effect profile [4].
Third- and fourth-generation fluoroquinolones have shown a better Gram-
positive coverage than ciprofloxacin while maintaining an adequate level of 
Gram-negative activity. Moxifloxacin has the most potent in vitro activity against 
Gram-negative and Gram-positive endophthalmitis pathogens [3–5]. It has been 
used as an intracameral antibiotic for cataract surgery prophylaxis, and there has 
been a three-fold decline in endophthalmitis rates with its use in phacoemulsifica-
tion surgery. It is increasingly being used as an alternative intravitreal antibiotic 
for APIE cases [31]. Furthermore, moxifloxacin has also exhibited adequate ocular 
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penetration after systemic administration, with vitreous levels above minimum 
inhibitory concentration (MIC90) for most bacteria [32].
Vitreous moxifloxacin pharmacokinetics have shown in several studies compara-
ble bioavailability characteristics to ciprofloxacin, with reasonable safety [4, 5, 32]. 
Moreover, cases of vancomycin-resistant bacteria have been reported to respond 
adequately to intravitreal injection of moxifloxacin [4, 5, 32].
Linezolid is an oxazolidinone-class antibiotic that the FDA approved in 2000 
[5, 33, 34]. It has excellent bioavailability when administered orally, and intra-
ocular levels can reach therapeutic levels within one hour of being administered. 
Linezolid provides mainly gram-positive coverage [5, 33]. If Gram-positive organ-
isms have shown resistance to vancomycin, it might be reasonable to supplement 
with oral linezolid, and likewise, oral ciprofloxacin or moxifloxacin may increase 
the antimicrobial properties of intravitreal ceftazidime [5, 33]. Other IAI used in 
animal models or humans for endophthalmitis include quinupristin-dalfopristin 
[5, 34–37], daptomycin [5, 38–40], tygecicline [5, 41], imipenem [5], among others 
[42, 43]. New antifungals for APIE, include miconazole, caspofungin, and mica-
fungin [5]. In Table 4, some of the antibiotics that have been used in endophthal-
mitis are summarized.
Another debated topic in APIE treatment is the use of steroid therapy. 
Experimental endophthalmitis animal models have shown that the degree of 
retinal tissue damage is partly secondary to the elicited severe inflammatory 
response in the eye [4]. Hence, it is appropriate to address this issue besides the 
use of antimicrobial therapy, and aggressive steroid therapy should be prescribed 
in APIE patients, which include topical 1% prednisolone acetate as frequently as 
every hour as well as oral steroids [3, 4, 44]. Cycloplegic topical medication such 
as 1% atropine, BID should be prescribed as well, to help decrease pain.
Controversy, however, still prevails regarding the use of intravitreal steroids 
in APIE. Some authors reported an improvement in inflammation and final 
visual results with intravitreal injection of steroids and antibiotics, whereas other 
studies have described worse inflammation and worse visual outcomes [44]. 
Histopathology reports have also shown contradictory outcomes for intravitreal 
steroids. In addition, intravitreal triamcinolone has been shown a favorable effect 
for APIE when combined with IAI in some reports [44].
Dexamethasone implants have been approved for use in several forms of uveitis, 
which has led to evaluate their possible use in endophthalmitis patients. Moisseiev 
et al. [45] reported APIE patients treated with immediate intravitreal dexametha-
sone at the time of vitreous tap. Compared to a group without steroid use, a trend 
towards the reduced need for antibiotic re-injection was observed in the steroid 
group. Currently, intravitreal dexamethasone recommended dose is 400 μg in 0.1 ml.
Antimicrobial Name Class of drugs Intravitreal dose
Antibiotics Vancomycin* Glycopeptide 1 mg/0.1 ml
Ceftazidime* Cephalosporin 2.25mgs/0.1 ml
Amikacin Aminoglycoside 0.4 mgs/0.1 ml
Antifungals Voriconazole Azol 50–100 μg/0.1 ml
Amphotericine B Polyene 5–10 μg/0.1 ml
*Vancomycin and ceftazidime are used as first-line treatment of acute postoperative endophthalmitis.
Table 3. 
Intravitreal antibiotics used for the management of acute postoperative infectious endophthalmitis [5]. 
Intravitreal injections of vancomycin and ceftazidime are currently recommended as first-line treatment in 
acute postoperative endophthalmitis.
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7.2 Vitrectomy for postoperative endophthalmitis
The EVS concluded that early vitrectomy in endophthalmitis was only beneficial 
in patients with visual acuity of light perception or worse [13]. Hence, delaying 
vitrectomy in APIE patients with a better presenting vision has been a common 
practice among retina specialists. Nonetheless, there is still debate on the adequate 
timing to perform vitrectomy in APIE patients.
The methods and results of EVS may not reflect modern surgery practice patterns. 
Furthermore, with the advent of more refined surgical techniques in recent years like 
minimally-invasive vitrectomy surgery (MIVS), which entail a lower complication 
rate compared to conventional vitrectomy, the EVS study’s conclusions are possibly 
obsolete. Currently, performing both vitrectomy and IAI as first-line treatments 
might be more beneficial for many APIE cases [6, 7, 27–29, 46].
In many hospital settings, vitrectomy is usually performed in those APIE 
patients that do not respond to an initial dose of IAI. In these patients, repeating 
IAIs instead of performing PPV is likely to be of little benefit. Persisting levels of 
vitreous antibiotic above MIC90 for three days or more after IAI and repeating the 
same agents after 2–3 days may be deleterious to the eye due to an increased risk 
of retina toxicity. In addition, some authors [47] have hypothesized that bacterial 
sequestering or biofilm production might reduce the bacteria’s sensitivity to IAI; 
furthermore, vitrectomy might help remove the bacterial load and increase antibi-
otic bioavailability in the vitreous cavity.
Peyman et al. were the first to report the use of early vitrectomy in endophthal-
mitis patients [48]. Cases underwent vitrectomy 24 hours after diagnosis, 65% 
achieving a final visual acuity of 20/400 or better.
The EVS evaluated the early vitrectomy role and contrasted immediate vit-
rectomy within six hours of diagnosis against inject-only as subgroups. Only 
core vitrectomy was performed on the included patients. While no advantage for 
Microorganism Name of drug Class of drug Intravitreal dose
Gram positive Linezolid Oxazolindinone 300 μg/0.1 ml
Quinupristine-dalfopristine Streptogramin 0.4 mg/0.1 ml





Gram negative Imipenem Carbapenem 50 μg/0.1 ml
Ciprofloxacin Fluoroquinolone 0.1 mg/0.1 ml
Levofloxacin Fluoroquinolone 0.1 ml 0.5% solution
Moxifloxacin* Fluoroquinolone 0.2 mg/0.1 ml
Fungi Miconazole Azole 25 μg/0.1 ml
Caspofungin Echinocandin 50 μg/0.1 ml
Micafungin Echinocandin 0.025 mg/0.1 ml
*Moxifloxacin is increasingly being used as part of APIE prophylaxis and as alternative intravitreal antibiotic in 
acute postoperative endophthalmitis cases [5, 30].
Table 4. 
Main alternative antibiotics for potential use in the management of endophthalmitis caused by resistant 
microorganisms to standard IAI. Evidence of their use comes from case reports and case series in humans and 
animal models.
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performing PPV was found unless vision was light perception or worse, no disad-
vantage in the final visual outcome was found in performing vitrectomy [13].
Moreover, the induction of a posterior hyaloid separation and a complete vitrec-
tomy were usually avoided in the EVS. Contrary to the EVS methods, some reports 
suggest that removing the posterior hyaloid and using silicone oil as a tamponade in 
APIE patients could improve anatomic and visual outcomes [13].
Kuhn et al. [46] described a series of patients who underwent early vit-
rectomy for endophthalmitis with a more thorough surgical vitrectomy and 
found no rhegmatogenous detachment cases. Ninety one percent of the cases 
had a final vision of 20/40 or better, contrary to 53% in the EVS study group. 
They postulated that removing the posterior vitreous cortex may remove the 
toxic load from proximity to the macula. Other case series have reached similar 
conclusions [6, 7, 27–29].
Current vitrectomy techniques include 23 Ga, 25 Ga, or 27 Ga MIVS rather than 
conventional 20 Ga techniques. In addition, some key points should be considered 
while performing vitrectomy in APIE patients:
First, because the media is frequently hazy for the surgeon to visualize a pars 
plana port, an infusion cannula sometimes cannot be used for the initial stages 
of the operation. It is advisable to place an inferotemporal port, reserving its use 
later in the procedure, once the tip’s location in the vitreous cavity can be verified. 
Alternatively, an anterior chamber maintainer could be placed.
Second, opacities such as hypopyon and pupillary membranes should be aspi-
rated from the anterior segment. Often, because of poor dilation of the pupil and 
visualization of the internal structures, the lens in phakic eyes must be removed. If 
the cornea remains too cloudy due to bacterial infiltration and inflammation, and it 
does not allow adequate visualization of the vitreous cavity, the use of keratopros-
thesis should sometimes be considered.
Third, separation of the posterior hyaloid besides core vitrectomy should be 
attempted in some APIE cases. Some authors [46] have described performing 
complete vitrectomy to help decrease inflammatory cells and bacterial loads. It can 
be achieved with current vitrectomy systems, using high-cutting rates and low-flow 
to lessen the retina traction while removing vitreous strands, thus minimizing the 
risk of iatrogenic retinal breaks, as well. Nonetheless, caution should still prevail 
in performing peripheral vitrectomy, and posterior hyaloid separation in cases 
where the retina appears too necrotic since the risk of formation of retinal tears may 
increase in this scenario.
Video 1 (https://youtu.be/Q0lLB4Ozkoc) shows an APIE case where hypopyon 
aspiration, core and peripheral 23 Ga PPV, as well as posterior hyaloid separation 
were performed.
Fifth, the use of silicone oil as a tamponade has been shown to have a bacteri-
cidal effect in vitro and may be worth considering in the context of performing PPV 
in APIE patients, especially if retinal tamponade is also required in cases of retinal 
detachment. However, silicone oil’s bactericidal effect has been challenging to prove 
in vivo [4, 6, 7, 27–29].
Another recently described surgical technique for endophthalmitis is endo-
scopic vitrectomy that uses an endoscopic probe inserted via pars plana to improve 
visualization in the vitreous cavity, identify intraocular structures, and avoid 
iatrogenic damage performing a PPV [49]. It has the advantage that it does not 
require clear anterior media, which is frequently compromised in endophthalmitis 
patients. It does not require waiting for media clearing, which carries an additional 
risk of tissue damage due to the infection and severe inflammation processes. 
Disadvantages of endoscopic vitrectomy include the steep curve for re-learning 
vitrectomy via an endoscope probe.
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If an early vitrectomy is performed because of initial non-response to IAI or 
removing inflammatory debris, it is common to inject antibiotics concomitantly 
into the vitreous cavity. Antibiotics can be injected at the end of the vitrectomy or 
via the diluted solution infused into the vitreous cavity throughout the vitrectomy 
procedure.
The patient may be left with saline solution, air, gas, or silicone oil as tampo-
nade. It is of the utmost relevance to consider that the volume of water-based fluid 
in the eye dictates the antibiotic’s amount and concentration [4, 6, 7, 27–29, 46]. 
This is because high antibiotic levels present in the remaining meniscus of aque-
ous fluid may increase toxicity risk to the retinal tissue that may eventually induce 
further vision loss. Therefore, it is essential to consider injecting a third or fourth 
of the recommended intravitreal antibiotic dose in patients with gas or silicone 
oil-filled eyes to obtain an antibiotic’s adequate concentration, as the concentration 
of the antibiotic changes in the small meniscus of aqueous fluid that will remain in 
the vitreous cavity.
Alternatively, antibiotic could be diluted at the proper concentration in the 
irrigation solution that enters the vitreous cavity, thus the remaining fluid will 
also have adequate antibiotic concentration. The antibiotic can be injected into the 
vitreous cavity before the tamponade [27–29, 46]. It may be necessary to position 
the patient face-down a few days after surgery to minimize macular exposure to 
antibiotics.
Some authors have described the successful use of infused vancomycin throughout 
vitrectomy at different concentrations. This approach might expose the retinal tissue 
to a more constant antibiotic level than an intravitreal injection. Nevertheless, it also 
may have the risk of using sub-therapeutic concentrations of the antibiotic [27].
7.3 Endophthalmitis prophylaxis
The single most effective prophylaxis of endophthalmitis includes preopera-
tive application of 5% povidone-iodine (PI) conjunctival surface and cul-de-sac 
[50–53]. Bacteria have not developed resistance to PI, and PI is also effective against 
many microorganisms such as fungi and viruses. Several studies have proven the 
effectiveness of the aseptic technique and the use of PI in ophthalmological surgery. 
One report assessed the incidence of APIE over many years in the same hospital 
with the incorporation of PI, with no use of intraocular antibiotics. Over this time, 
the rate of APIE went from 0.38% to <0.03%. This rate is almost the same as the 
current studies looking into risk reduction using intracameral antibiotics [51].
Checking for lid infections like blepharitis, nasolacrimal duct obstruction, 
leaking wounds, and intracameral antibiotics like cefuroxime 1000 μg/0.1 ml or 
moxifloxacin at the end of the surgery, and the use topical postoperative antibiotics 
are some other measures that might decrease endophthalmitis incidence [3, 4].
A large study of eyes that underwent cataract surgery [54] showed that intra-
cameral moxifloxacin declined postcataract surgery endophthalmitis incidence. 
Nonetheless, the routinary application of intracameral antibiotics has some risks, 
such as the development of resistant strains of pathogens, and retinal toxicity. For 
instance, hemorrhagic occlusive retinal vasculitis has been described after using 
intracameral vancomycin [53].
The most common causative bacteria in post intravitreal injections endophthal-
mitis are streptococci, common oral flora members. The use of masks and adhering 
to a strict no-talking policy has decreased post-injection endophthalmitis incidence.
Prompt surgical repair of open globe injuries and prophylactic IAI with or 
without systemic antibiotics have also been associated with reduced post-traumatic 
endophthalmitis incidence.
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7.4 Other novel treatments and developments
Nakashizuka et al. [52] reported the safety and efficacy of 1.25% povidone-
iodine (PI) intravitreal injection followed by vitrectomy using 0.025% irrigation 
to treat endophthalmitis. Most of the cases included in the study resolved rapidly, 
and good visual results were observed. No adverse events were reported. Moreover, 
the electrorretinogram (ERG) results showed increases in the oscillatory potentials 
amplitudes, flicker ERG and the a-wave’s implicit time, suggesting the functional 
improvement in the retinal inner and outer layers after surgery. They concluded 
that intravitreal injection of PI followed by PPV was thought to be an effective and 
safe therapy for APIE. Other authors have reported similar findings [52, 53].
Other novel therapies under investigation for APIE include the development of 
microdevices such as biomimetic nanosponge to treat endophthalmitis caused by 
virulent pathogens such as Enterococcus faecalis isolates. Enterococcus faecalis pro-
duces the pore-forming bicomponent cytolysin that adds to retinal tissue damage in 
endophthalmitis. LaGrow et al. [55] hypothesized that a biomimetic nanosponge, 
which imitates erythrocytes, could adsorb subunits of the cytolysin and decrease 
damage to the retina, preserving vision in endophthalmitis patients.
They reported that biomimetic nanosponges nullified cytolysin activity and pro-
tected the retinal tissue from damage. These outcomes indicate that this therapeutic 
option could guard eyes against the deleterious effects of pore-forming toxins of 
various aggressive ocular bacteria [55].
8. Prognosis of acute postoperative endophthalmitis
One of the most important predictors of final visual outcome is presenting 
visual acuity. Patients with presenting vision of light perception or worse may have 
worse outcomes [3, 4]. Therefore, prompt treatment of endophthalmitis cases is 
associated with improved visual acuity outcomes. Prompt initiation of therapy is 
more important than any other factor, including PPV versus vitreous tap or the use 
of adjunctive systemic antibiotics.
Other predictors of worse visual outcomes include DM, older age, corneal 
infiltrate, high or low intraocular pressure, rubeosis iridis, an absent red reflex, 
and an open posterior capsule. Dense vitreous opacities, and vitreous mem-
branes, retinal detachment, are also associated with a more unsatisfactory visual 
outcome [4].
9. Conclusions
Although many breathtaking advances have been described and applied for APIE 
treatment, further measures and prophylactic strategies are needed to decrease the inci-
dence and improve the prognosis of this devastating complication of intraocular surgery.
Novel molecular biology techniques like RT-PCR have been developed to aid in 
the etiologic diagnosis of endophthalmitis, which has improved and expedited APIE 
patients’ antibiotic treatment.
Advances in vitreoretinal surgery techniques such as the advent of MIVS and 
other improvements in vitrectomy systems have changed our way of thinking about 
early vitrectomy in the treatment of these patients.
However, controversy still prevails on many issues, such as the role of steroid 
use, vitrectomy timing, and the incorporation of other innovative diagnostic and 
therapeutic modalities for APIE.
Infectious Eye Diseases - Recent Advances in Diagnosis and Treatment
14
Author details
Sergio E. Hernandez-Da Mota1*, Jose Luis Guerrero-Naranjo2,  
Jose Dalma-Weiszhausz2, Raul Velez-Montoya2 and Jesus H. Gonzalez-Cortes3
1 Retina Department, David Clinic and Michoacan University School of Medicine 
“Dr. Ignacio Chavez”, Morelia, Mexico
2 “Dr. Luis Sanchez Bulnes” Hospital, APEC, National Autonomous University of 
Mexico (UNAM), Mexico City, Mexico
3 Ophthalmology Department, Dr. Jose Eleuterio Gonzalez University Hospital, 
Autonomous University of Nuevo Leon, Monterrey, Mexico
*Address all correspondence to: tolodamota@yahoo.com.mx
Conflict of interest
The authors have no conflicts of interest to declare.
Nomenclature
Anti-VEGF Anti-Vascular Endothelial Growth Factor
APIE Acute Postoperative Infectious Endophthalmitis
DM Diabetes Mellitus
EVS Endophthalmitis Vitrectomy Study
ERG Electroretinogram
IAI Intravitreal Antibiotic Injection
MIVS Minimally-invasive Vitrectomy Surgery
MGST-PCR Multiplex Gram-Specific TaqMan–Based PCR
PCR Polymerase Chain Reaction
RT-PCR Real-Time Polymerase Chain Reaction
SGRU-PCR Green 16S rDNA–Based Universal PCR
PPV Pars Plana Vitrectomy
PI Povidone-Iodine
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Acute Postoperative Infectious Endophthalmitis: Advances in Diagnosis and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.97545
[1] Schwartz SG, Flynn HW Jr, Das T, 
Mieler WF. Ocular Infection: 
Endophthalmitis. Dev Ophthalmol. 
2016;55:176-88. DOI: 10.1159/000431195
[2] Packer M, Chang DF, Dewey SH, 
Little BC, Mamalis N, Oetting TA, 
Talley-Rostov A, Yoo SH; ASCRS 
Cataract Clinical Committee. 
Prevention, diagnosis, and management 
of acute postoperative bacterial 
endophthalmitis. J Cataract Refract 
Surg. 2011;37:1699-714. DOI: 10.1016/j.
jcrs.2011.06.018
[3] Meredith TA, Ulrich JN. Infectious 
endophthalmitis. In: Wilkinson CP, 
Hinton DR, Sadda SR, Wiedemann P, 
editors. Ryan’s Retina. 6th ed. 
Amsterdam:Elsevier; 2018. p. 
2266-2281.
[4] Eichenbaum DA, Park RI, 
Topping TM. Postoperative 
endophthalmitis. In: Steinert RF, editor. 
Cataract surgery. 3rd ed. Saunders-
Elsevier; 2010. p. 671-680.
[5] Relhan N, Pathengay A, 
Schwartz SG, Flynn HW. Emerging 
Worldwide Antimicrobial Resistance, 
Antibiotic Stewardship and Alternative 
Intravitreal Agents for the Treatment of 
Endophthalmitis. Retina. . 2017;37:811-
818. DOI: 10.1097/IAE.0000000 
000001603
[6] Relhan N, Forster RK, Flynn HW Jr. 
Endophthalmitis: Then and Now. Am J 
Ophthalmol. 2018;187:20-27. DOI: 
10.1016/j.ajo.2017.11.021
[7] Clarke B, Williamson TH, Gini G, 
Gupta B. Management of bacterial 
postoperative endophthalmitis and the 
role of vitrectomy. Surv Ophthalmol. 
2018;63:677-693. DOI: 10.1016/j.
survophthal.2018.02.003
[8] Gedde SJ, Herndon LW, Brandt JD, 
Budenz DL, Feuer WJ, Schiffman JC, 
Tube Versus Trabeculectomy Study 
Group. Postoperative complications in 
the tube versus trabeculectomy (TVT) 
study during five years of follow up. Am 
J Ophthalmol. 2012;153:804-814. 
DOI:10.1016/j. ajo.2011.10.024
[9] Olayanju JA, Hassan MB, Hodge DO, 
Khanna CL. Trabeculectomy related 
complications in Olmsted County, 
Minnesota, 1985-2010. JAMA 
Ophthalmol. 2015;133 (5):574-580. 
DOI:10.1001/jamaophthalmol. 
2015.57
[10] Borkar DS, Wibbelsman TD, 
Buch PM, Rapuano SB, Obeid A, 
Ho AC, et al. Endophthalmitis Rates and 
Clinical Outcomes Following 
Penetrating and Endothelial 
Keratoplasty. Am J Ophthalmol. 
2019;205:82-90. DOI: 10.1016/j.
ajo.2019.05.004.
[11] Cao H, Zhang L, Li L, Lo S. Risk 
factors for acute endophthalmitis 
following cataract surgery: A systematic 
review and meta-analysis. PLoS One. 
2013;8(8):e71731. DOI:10.1371/journal.
pone.0071731
[12] Rahmani S, Eliott D. Postoperative 
Endophthalmitis: A Review of Risk 
Factors, Prophylaxis, Incidence, 
Microbiology, Treatment, and 
Outcomes. Review Semin Ophthalmol. 
2018;33:95-101. DOI: 10.1080/ 
08820538.2017.1353826
[13] Han DP, Wisniewski SR, Wilson, 
Barza M, Vine AK, Doft BH, Kelsey SF. 
Spectrum and susceptibilities of 
microbiologic isolates in the 
Endophthalmitis Vitrectomy Study, Am 
J Ophthalmol. 1996; 122:1-17. DOI: 
10.1016/s0002-9394(14)71959-2
[14] O’Callaghan RJ. The Pathogenesis of 
Staphylococcus aureus Eye Infections. 
Pathogens. 2018;7:9. DOI: 10.3390/
pathogens7010009
References
Infectious Eye Diseases - Recent Advances in Diagnosis and Treatment
16
[15] Astley R, Miller FC, Mursalin MH, 
Coburn PS, Callegan MC. An Eye on 
Staphylococcus aureus Toxins: Roles in 
Ocular Damage and Inflammation. 
Toxins (Basel). 2019;11:356. DOI: 
10.3390/toxins11060356
[16] Choi JA, Chung SK. Postoperative 
Endophthalmitis following Cataract 
Surgery in Asia. ISRN Ophthalmol. 
2011;2011:917265. DOI: 
10.5402/2011/917265
[17] Cornut PL, Boisset S, Romanet JP, 
Maurin M, Carricajo A, Benito Y, 
Vandenesch F, Chiquet C. Principles and 
applications of molecular biology 
techniques for the microbiological 
diagnosis of acute postoperative 
endophthalmitis. Surv Ophthalmol. 
2014;59:286-303. DOI: 10.1016/j.
survophthal.2013.08.002
[18] Ogawa M, Sugita S, Shimizu N, 
Watanabe K, Nakagawa I, Mochizuki M. 
Broad-range real-time PCR assay for 
detection of bacterial DNA in ocular 
samples from infectious 
endophthalmitis. Jpn J Ophthalmol. 
2012; 56:529-535. DOI: 10.1007/
s10384-012-0174-z
[19] Bispo PJM, de Melo GB, Ho 
ing-Lima AL, Pignatari ACC. Detection 
and gram discrimination of bacterial 
pathogens from aqueous and vitreous 
humor using real-time PCR assays. 
Invest Ophthalmol Vis Sci. 2011;52:873-
881. DOI: 10.1167/iovs.10-5712
[20] Ogawa M, Sugita S, Watanabe K, 
Shimizu N, Mochizuki M. Novel 
diagnosis of fungal endophthalmitis by 
broad-range real-time PCR detection of 
fungal 28S ribosomal DNA. Graefes 
Arch Clin Exp Ophthalmol. 
2012;250:1877-1883. DOI: 10.1007/
s00417-012-2015-7
[21] Sugita S, Kamoi K, Ogawa M, 
Watanabe K, Shimizu N, Mochizuki M. 
Detection of Candida and Aspergillus 
species DNA using broad-range real-
time PCR for fungal endophthalmitis. 
Graefes Arch Clin Exp Ophthalmol. 
2012;250:391-398. DOI: 10.1007/
s00417-011-1819-1
[22] Nandi K, Ranjan P, Therese L, 
Biswas J. Polymerase chain reaction in 
intraocular inflammation. Open 
Ophthalmol J. 2008;2:141-5. DOI: 
10.2174/1874364100802010141
[23] Biwas J, Bagyalakshmi R, 
Therese LK. Diagnosis of Aspergillus 
fumigatus endophthalmitis from 
formalin fixed paraffin-embedded 
tissue by polymerase chain reaction-
based restriction fragment length 
polymorphism. Indian J 
Ophthalmol.2008;56:65-6. DOI: 
10.4103/0301-4738.37600
[24] Lacroix C, Gicquel A, Sendid B, 
Meyer J, Accoceberry I, François N, 
Morio F, Desoubeaux G, Chandenier J, 
Kauffmann-Lacroix C, Hennequin C, 
Guitard J, Nassif X, Bougnoux ME. 
Evaluation of two matrix- assisted laser 
desorption ionization-time of ight mass 
spectrometry (MALDI-TOF MS) 
systems for the identi cation of Candida 
species. Clin Microbiol Infect. 
2014;20:153-158. DOI: 
10.1111/1469-0691.12210
[25] Seng P, Abat C, Rolain JM, Colson P, 
Lagier JC, Gouriet F, Fournier PE, 
Drancourt M, La Scola B, Raoult D. 
Identification of rare pathogenic 
bacteria in a clinical microbiology 
laboratory: impact of MALDI-TOF mass 




[26] Chung HJ, Castro CM, Im H, Lee H, 
Weissleder R. A magneto-DNA 
nanoparticle system for rapid detection 
and phenotyping of bacteria. Nat 
Nanotechnol. 2013;8:369-375. DOI: 
10.1038/nnano.2013.70
17
Acute Postoperative Infectious Endophthalmitis: Advances in Diagnosis and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.97545
[27] Clarke B, Williamson TH, Gini G, 
Gupta B. Management of bacterial 
postoperative endophthalmitis and the 
role of vitrectomy. Surv Ophthalmol. 
2018;63:677-693. DOI: 10.1016/j.
survophthal.2018.02.003
[28] Park JC, Ramasamy B, Shaw S, 
Ling RH, Prasad S. A prospective and 
nationwide study investigating 
endophthalmitis following pars plana 
vitrectomy: Clinical presentation, 
microbiology, management and 
outcome. Br J Ophthalmol. 
2014;98:1080-1086. DOI:10.1136/
bjophthalmol-2013-304486
[29] Grzybowski A, Turczynowska M, 
Kuhn F. The treatment of postoperative 
endophthalmitis: should we still follow the 
endophthalmitis vitrectomy study more 
than two decades after its publication? 
Acta Ophthalmol. 2018;96:e651-e654. 
DOI: 10.1111/aos.13623
[30] Doft BH, Barza M. Optimal 
management of postoperative 
endophthalmitis and results of the 
Endophthalmitis Vitrectomy Study. 
Curr Opin Ophthalmol. 1996;7:84-94. 
DOI: 10.1097/00055735-199606000- 
00015
[31] Haripriya A, Baam ZR, Chang DF. 
Endophthalmitis Prophylaxis for 
Cataract Surgery. Asia Pac J Ophthalmol 
(Phila). 2017;6:324-329. DOI: 10.22608/
APO.2017200
[32] Sharma T, Kamath MM, 
Kamath MG, Nayak RR, Bairy KL, 
Musmade PB. Aqueous penetration of 
orally and topically administered 
moxifloxacin. Br J Ophthalmol. 
2015;99:1182-5. DOI: 10.1136/
bjophthalmol-2014-306502
[33] Duke SL, Kump LI, Yuan Y, et al. 
The safety of intraocular linezolid in 
rabbits. Invest Ophthalmol Vis Sci 
2010;51:3115-3119. DOI: 10.1167/
iovs.09-4244
[34] Babalola OE. Intravitreal linezolid 
in the management of vancomycin-
resistant enterococcal endophthalmitis. 
Am J Ophthalmol Case Rep. 
2020;20:100974. DOI: 10.1016/j.
ajoc.2020.100974
[35] Hernandez-Da Mota SE. 
Quinupristin/dalfopristin in 
Staphylococcus aureus endophthalmitis: 
a case report. J Med Case Rep. 
2011;5:130. DOI: 10.1186/1752- 
1947-5-130
[36] Stroh EM. Quinupristin/dalfopristin 
in vancomycin-resistant Staphylococcus 
aureus endophthalmitis. Arch 
Ophthalmol 2012;130:1323-1324. DOI: 
10.1001/archophthalmol.2012.1504
[37] Giordano VE, Hernandez-Da 
Mota SE, Adabache-Guel TN, 
Castillejos-Chevez A, Corredor-Casas S, 
Salinas-Longoria SM, Romero-Vera R, 
Jimenez-Sierra JM, Guerrero- 
Naranjo JL, Morales-Canton V. Safety of 
intravitreal quinupristin/dalfopristin in 
an animal model. Int J Ophthalmol 
2016;9:373-378. DOI: 10.18240/
ijo.2016.03.08
[38] Buzzacco DM, Carroll CP. 
Intravitreal daptomycin in a case of 
bilateral endogenous endophthalmitis. 
Arch Ophthalmol 2012;130:940-941. 
DOI: 10.1001/archophthalmol.2011.2527
[39] Sim JM, Kapoor KG, Wagner AL. 
Intravitreal daptomycin for recalcitrant 
postoperative endophthalmitis. Case 
Rep Ophthalmol 2016;7:103-107. DOI: 
10.1159/000444046
[40] Comer GM, Miller JB, 
Schneider EW, Khan NW, Reed DM, 
Elner VM, Zacks DN. Intravitreal 
daptomycin: a safety and efficacy study. 
Retina 2011;31:1199-1206. DOI: 10.1097/
IAE.0b013e318207d1b9
[41] Horozoglu F, Metan G, Sever O, 
Percin D, Topal CS, Gonen T, 
Infectious Eye Diseases - Recent Advances in Diagnosis and Treatment
18
Keskinbora KH, Topcu B, Yanyali A. 
Intravitreal tigecycline treatment in 
experimental Acinetobacter baumannii 
endophthalmitis. J Chemother 
2012;24:101-106. DOI: 10.1179/ 
1120009X12Z.00000000018
[42] Aziza Y, Kodrat E, Saharman YR, 
Setiabudy R, Susiyanti M, Sjamsoe S. 
Efficacy of intravitreal Levofloxacin 
0.5% ophthalmic solution in treating 
Pseudomonas aeruginosa endophthalmitis 
on a rabbit model. Asia Pac J 
Ophthalmol (Phila) 2013;2:199-205. 
DOI: 10.1097/APO.0b013e3182970cc9
[43] Ozkiriş A, Evereklioglu C, Eşel D, 
Akgün H, Erkiliç K. The efficacy of 
intravitreal piperacillin/tazobactam in 
rabbits with experimental Staphylococcus 
epidermidis endophthalmitis: a 
comparison with vancomycin. 
Ophthalmic Res. 2005;37:168-74. DOI: 
10.1159/000086074.
[44] Ching Wen Ho D, Agarwal A, 
Lee CS, Chhablani J, Gupta V, Khatri M, 
Nirmal J, Pavesio C, Agrawal R. A 
Review of the Role of Intravitreal 
Corticosteroids as an Adjuvant to 
Antibiotics in Infectious 
Endophthalmitis. Ocul Immunol 
Inflamm. 2018;26:461-468. DOI: 
10.1080/09273948.2016.1245758
[45] Moisseiev E, Abbassi S, Park SS. 
Intravitreal dexamethasone in the 
management of acute endophthalmitis: 
a comparative retrospective study. Eur J 
Ophthalmol. 2017;27:67-73. DOI: 
10.5301/ejo.5000866.




[47] Leung EH, Gibbons A. 
Environmental, Local, and Systemic 
Endophthalmitis Prophylaxis for 
Cataract Surgery. Int Ophthalmol Clin. 
2020;60:113-126. DOI: 10.1097/
IIO.0000000000000327
[48] Peyman GA, Rose M, Sanders D. 
Intravitreal antibiotic injection and 
vitrectomy in acute bacterial 
endophthalmitis. Can J Ophthalmol. 
1976;11:188-90.
[49] Dave VP, Pappuru RR, Tyagi M, 
Pathengay A, Das T. Endoscopic 
vitrectomy in endophthalmitis: initial 
experience of 33 cases at a tertiary eye 
care center. Clin Ophthalmol. 
2019;13:243-251. DOI: 10.2147/
OPTH.S185716
[50] Otani K, Shimada H, 
Nakashizuka H, Okubo H Capsular bag 
irrigation using 0.025% povidone-
iodine in balanced salt solution PLUS for 
the treatment of postoperative 
endophthalmitis. Int Ophthalmol. 
2018;38:1787-1790. DOI: 10.1007/
s10792-017-0645-9
[51] Shimada H, Hattori T, Mori R, 
Nakashizuka H, Fujita K, Yuzawa M. 
Minimizing the endophthalmitis rate 
following intravitreal injections using 
0.25% povidone-iodine irrigation and 
surgical mask. Graefes Arch Clin Exp 
Ophthalmol. 2013;251:1885-90. DOI: 
10.1007/s00417-013-2274
[52] Nakashizuka H, Shimada H, 
Hattori T, Noguchi T, Kokubo N, 
Yuzawa M. Vitrectomy using 0.025% 
povidone-iodine in balanced salt 
solution plus for the treatment of 
postoperative endophthalmitis. Retina. 
2015;35:1087-94. DOI: 10.1097/
IAE.0000000000000634
[53] Grzybowski A, Schwartz SG, 
Matsuura K, Ong Tone S, Arshinoff S, 
Ng JQ , et al. Endophthalmitis 
Prophylaxis in Cataract Surgery: 
Overview of Current Practice Patterns 
Around the World. Curr Pharm Des. 
2017;23:565-573. DOI: 10.2174/13816128
22666161216122230
[54] Melega MV, Alves M, Cavalcanti 
Lira RP, Cardoso da Silva I, Ferreira BG, 
Assis Filho HL, et al. Safety and efficacy 
19
Acute Postoperative Infectious Endophthalmitis: Advances in Diagnosis and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.97545
of intracameral moxifloxacin for 
prevention of post-cataract 
endophthalmitis: Randomized 
controlled clinical trial. J Cataract 
Refract Surg. 2019;45:343-350. DOI: 
10.1016/j.jcrs.2018.10.044
[55] LaGrow AL, Coburn PS, Miller FC, 
Land C, Parkunan SM, Luk BT, Gao W, 
Zhang L, Callegan MC.A Novel 
Biomimetic Nanosponge Protects the 
Retina from the Enterococcus faecalis 
cytolysin. mSphere. 2017;2:e00335-17. 
DOI: 10.1128/mSphere.00335-17
